Hydrochloride pioglitazone decreases urinary TGF-β1 excretion in type 2 diabetics

European Journal of Clinical Investigation

Volumn 40, Issue 7, 2010, Pages 571-574

  Hu, Yuan Yuan ^a   Ye, Shan Dong ^a   Zhao, Li Li ^a   Zheng, Mao ^a   Chen, Yan ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Diabetic nephropathy; Pioglitazone; Transforming growth factor 1

Indexed keywords

CREATININE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953498800     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02302.x     Document Type: Article

References (18)

1. Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. Singapore Med J 2009 50: 395 399.
2. Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006 55: 1666 1677.
3. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005 16: 638 645.
4. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007 71: 1232 1239.
5. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007 292: F1141 50.
6. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 2009 24: 2384 2349.
7. Lee MY, Lee EY, Lee BJ, Won CS, Koh JH, Shin JY et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J 2007 48 (2 301 715.
8. Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008 23: 2750 2760.
9. Oh JH, Ha H, Yu MR, Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int 1998 54: 1872 1878.
10. Ha H, Lee HB. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology(Carlton) 2005 10 (Suppl S7 10.
11. Han J-S, Choi B-S, Yang C-W, Kim YS. Aldosterone-induced TGF-β1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci 2009 24 (Suppl 1 S195 203.
12. Durvasula RV, Petermann AT, Hiromura K, Blonski M. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004 65: 30 9.
13. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int, 2000 58 (Suppl 77 S59 66.
14. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004 15 (Suppl 1 S55 7.
15. Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viberti G et al. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant 2009 24: 2645 2655.
16. Wang WM, Zhang HD, Jin YM, Zhu BB, Chen N. PPAR-γ agonists inhibit TGF-β1-induced chemokine expression in human tubular epithelial cells. Acta Pharmacol Sin 2009 30 (1 107 112.
17. Panchapakesan U, Sumual S, Pollock CA, Chen X. PPARγ agonists exert anti-fibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005 289: F1153 8.
18. Wang W, Liu F, Chen N. Effects of peroxisome proliferators-activated receptor gamma agonists on transforming growth factor-beta1 and Smads signal pathway: experiment with rat renal fibroblasts. Zhonghua Yi Xue Za Zhi 2006 86: 740 744.